PE20161378A1 - Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y transtornos relacionados - Google Patents
Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y transtornos relacionadosInfo
- Publication number
- PE20161378A1 PE20161378A1 PE2016001909A PE2016001909A PE20161378A1 PE 20161378 A1 PE20161378 A1 PE 20161378A1 PE 2016001909 A PE2016001909 A PE 2016001909A PE 2016001909 A PE2016001909 A PE 2016001909A PE 20161378 A1 PE20161378 A1 PE 20161378A1
- Authority
- PE
- Peru
- Prior art keywords
- diabetes
- treatment
- related disorders
- dyslipidemia
- obesity
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 title 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 title 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 title 1
- 208000017170 Lipid metabolism disease Diseases 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- BZTCOPSYZMYFRZ-GOSISDBHSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=CC=2N(C1)N=C(N2)C2CC2)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=CC=2N(C1)N=C(N2)C2CC2)=O BZTCOPSYZMYFRZ-GOSISDBHSA-N 0.000 abstract 1
- DLMYMGJZUDAJFX-MRXNPFEDSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=CC=2N(C1)N=CN2)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=CC=2N(C1)N=CN2)=O DLMYMGJZUDAJFX-MRXNPFEDSA-N 0.000 abstract 1
- 101000829779 Homo sapiens Probable G-protein coupled receptor 19 Proteins 0.000 abstract 1
- 102100023417 Probable G-protein coupled receptor 19 Human genes 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305494 | 2014-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161378A1 true PE20161378A1 (es) | 2016-12-26 |
Family
ID=50513859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001909A PE20161378A1 (es) | 2014-04-04 | 2015-04-02 | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y transtornos relacionados |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9758520B2 (enExample) |
| EP (1) | EP3126336B1 (enExample) |
| JP (1) | JP2017509679A (enExample) |
| KR (1) | KR20160132885A (enExample) |
| CN (1) | CN106164073A (enExample) |
| AR (1) | AR099936A1 (enExample) |
| AU (1) | AU2015239021A1 (enExample) |
| CA (1) | CA2942753A1 (enExample) |
| CL (1) | CL2016002497A1 (enExample) |
| CR (1) | CR20160460A (enExample) |
| DO (1) | DOP2016000212A (enExample) |
| EA (1) | EA030410B1 (enExample) |
| EC (1) | ECSP16078779A (enExample) |
| IL (1) | IL248129A0 (enExample) |
| MA (1) | MA39346B1 (enExample) |
| MX (1) | MX2016013033A (enExample) |
| PE (1) | PE20161378A1 (enExample) |
| PH (1) | PH12016501619A1 (enExample) |
| SG (1) | SG11201606758SA (enExample) |
| TW (1) | TW201625605A (enExample) |
| WO (1) | WO2015150564A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106132953B (zh) | 2014-04-04 | 2019-03-22 | H.隆德贝克有限公司 | 作为pde1抑制剂的卤化的喹唑啉-thf-胺 |
| TW201625605A (zh) | 2014-04-04 | 2016-07-16 | 賽諾菲公司 | 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類 |
| AR109514A1 (es) | 2016-09-09 | 2018-12-19 | Zealand Pharma As | Análogos de amilina |
| AR110988A1 (es) | 2017-02-21 | 2019-05-22 | Sanofi Sa | Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados |
| WO2019043635A1 (en) | 2017-09-01 | 2019-03-07 | Richter Gedeon Nyrt. | COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE |
| LT3804714T (lt) * | 2018-05-31 | 2025-03-10 | Hua Medicine (Shanghai) Ltd. | Farmacinis derinys ir kompozicija, ir derinio preparatas, kurio sudėtyje yra gliukokinazės aktyvatorius ir biguanido hipoglikeminis vaistas, taip pat jų gamybos būdas ir panaudojimas |
| KR102131359B1 (ko) * | 2018-09-07 | 2020-07-07 | 오토텔릭바이오 주식회사 | 안정성이 향상된 의약 조성물 |
| US11248001B2 (en) | 2019-01-18 | 2022-02-15 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| EA202191890A1 (ru) | 2019-01-18 | 2022-02-03 | Астразенека Аб | Ингибиторы pcsk9 и способы их применения |
| CN114450011B (zh) * | 2019-05-31 | 2024-10-22 | 阿沃林特有限公司 | 用于治疗代谢性疾病的组合物和方法 |
| TWI867086B (zh) * | 2019-11-05 | 2024-12-21 | 加拿大商瑞斯弗洛吉克斯公司 | 以rvx-208及sglt2抑制劑治療及/或預防主要不良心血管事件(mace)的方法 |
| CA3173731A1 (en) | 2020-02-28 | 2021-09-02 | Kallyope, Inc. | Gpr40 agonists |
| CN116323608A (zh) | 2020-05-19 | 2023-06-23 | 卡尔优普公司 | Ampk活化剂 |
| EP4172162A4 (en) | 2020-06-26 | 2024-08-07 | Kallyope, Inc. | AMPK ACTIVATORS |
| JP7858636B2 (ja) | 2020-09-10 | 2026-05-14 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| MX2024005969A (es) | 2022-05-30 | 2024-06-11 | Zealand Pharma As | Formulaciones liquidas de analogos de amilina. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004110994A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Products Inc. | Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams |
| CA2647677C (en) * | 2006-04-21 | 2014-03-18 | Eli Lilly And Company | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
| SG185615A1 (en) * | 2010-05-17 | 2012-12-28 | Array Biopharma Inc | Piperidinyl-substituted lactams as gpr119 modulators |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| BR112013006344A2 (pt) | 2010-09-17 | 2016-06-21 | Array Biopharma Inc | lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas |
| EP2776039A2 (en) | 2011-11-11 | 2014-09-17 | GlaxoSmithKline LLC | Treatment of blood lipid abnormalities and other conditions |
| TW201625605A (zh) | 2014-04-04 | 2016-07-16 | 賽諾菲公司 | 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類 |
-
2015
- 2015-04-01 TW TW104110619A patent/TW201625605A/zh unknown
- 2015-04-01 AR ARP150100989A patent/AR099936A1/es unknown
- 2015-04-02 EA EA201692008A patent/EA030410B1/ru not_active IP Right Cessation
- 2015-04-02 SG SG11201606758SA patent/SG11201606758SA/en unknown
- 2015-04-02 CN CN201580017438.3A patent/CN106164073A/zh active Pending
- 2015-04-02 MX MX2016013033A patent/MX2016013033A/es unknown
- 2015-04-02 CA CA2942753A patent/CA2942753A1/en not_active Abandoned
- 2015-04-02 KR KR1020167026911A patent/KR20160132885A/ko not_active Withdrawn
- 2015-04-02 WO PCT/EP2015/057414 patent/WO2015150564A1/en not_active Ceased
- 2015-04-02 PE PE2016001909A patent/PE20161378A1/es not_active Application Discontinuation
- 2015-04-02 JP JP2016560725A patent/JP2017509679A/ja not_active Abandoned
- 2015-04-02 CR CR20160460A patent/CR20160460A/es unknown
- 2015-04-02 AU AU2015239021A patent/AU2015239021A1/en not_active Abandoned
- 2015-04-02 EP EP15713528.6A patent/EP3126336B1/en active Active
- 2015-04-02 MA MA39346A patent/MA39346B1/fr unknown
-
2016
- 2016-08-15 DO DO2016000212A patent/DOP2016000212A/es unknown
- 2016-08-15 PH PH12016501619A patent/PH12016501619A1/en unknown
- 2016-09-29 IL IL248129A patent/IL248129A0/en unknown
- 2016-09-30 CL CL2016002497A patent/CL2016002497A1/es unknown
- 2016-10-03 US US15/284,213 patent/US9758520B2/en not_active Expired - Fee Related
- 2016-10-04 EC ECIEPI201678779A patent/ECSP16078779A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2016000212A (es) | 2016-11-15 |
| TW201625605A (zh) | 2016-07-16 |
| CR20160460A (es) | 2017-02-21 |
| EA201692008A1 (ru) | 2017-02-28 |
| US9758520B2 (en) | 2017-09-12 |
| AU2015239021A1 (en) | 2016-10-13 |
| PH12016501619A1 (en) | 2017-02-06 |
| EP3126336A1 (en) | 2017-02-08 |
| MA39346A1 (fr) | 2017-09-29 |
| EP3126336B1 (en) | 2018-12-05 |
| CL2016002497A1 (es) | 2017-03-31 |
| CA2942753A1 (en) | 2015-10-08 |
| MX2016013033A (es) | 2017-01-09 |
| SG11201606758SA (en) | 2016-09-29 |
| ECSP16078779A (es) | 2017-02-24 |
| IL248129A0 (en) | 2016-11-30 |
| WO2015150564A1 (en) | 2015-10-08 |
| JP2017509679A (ja) | 2017-04-06 |
| US20170022198A1 (en) | 2017-01-26 |
| MA39346B1 (fr) | 2019-03-29 |
| EA030410B1 (ru) | 2018-07-31 |
| AR099936A1 (es) | 2016-08-31 |
| KR20160132885A (ko) | 2016-11-21 |
| CN106164073A (zh) | 2016-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170333A1 (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
| PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| PE20080263A1 (es) | Compuestos de pirrolo-pirimidina y sus usos | |
| PE20181074A1 (es) | Compuestos heteroaromaticos como inhibidores de btk | |
| CL2017000263A1 (es) | Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carbox-amida y su purificación para su uso como principio activo farmacéutico | |
| PE20170144A1 (es) | 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet | |
| AR061923A1 (es) | Compuestos derivados de benzofuran-piperidina | |
| GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
| PE20160844A1 (es) | Compuestos triciclicos como agentes anticancerigenos | |
| PE20141360A1 (es) | Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos. | |
| CO2017003132A2 (es) | Inhibidores de la aldosterona sintasa derivados de la 2,6-diazaspiro[3.3]heptán-6-il]-3-piridil]isoindolín-1-ona o 2,7-diazaspiro[3.5]nonán-2-il]-3-piridil]isoindolín-1-ona | |
| CR20140082A (es) | Polimorfos de inhibidores de cinasas | |
| ECSP099461A (es) | Compuesto heteromonocíclico y uso del mismo | |
| CL2009000916A1 (es) | Compuestos derivados de 2-trifluorometil-1h-indol-5-metilcarboxamida, moduladores del receptor nicotinico de acetilcolina alfa7 (nachr); composicon farmaceutica; y uso para el tratamiento del deterioro cognitivo y de un trastorno psicotico como esquizofrenia. | |
| PE20090188A1 (es) | Compuestos heterociclicos como moduladores de la senda de hedgehog | |
| AR069595A1 (es) | Compuestos amida como refuerzos de antivirales | |
| EA201792374A1 (ru) | Азабензимидазолы и их применение в качестве модуляторов рецептора ampa | |
| CO6361937A2 (es) | Derivados de heteroaril amidas y sus usos como activadores de glucoquinasa | |
| PE20170899A1 (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr 139 | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| CO7280468A2 (es) | Antagonistas del receptor de 5-ht3 | |
| ECSP16078779A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
| CL2013003211A1 (es) | Compuestos derivados de2,7 -diaza espiro(4.5)-decano, 2,7(diaza(4.5)-nonano; composicin farmaceutica; utiles en el tratamiento de enfermedades o trastornos mediadospor ele receptor de la gherelina, tales como gastroparesia, ileo, dispepsia funcional, sindrome del intestino corto, enre otras. | |
| CO2018000798A2 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| PE20141578A1 (es) | Derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas del receptor de canabinoides 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |